Literature DB >> 6981375

In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins.

H C Neu, P Labthavikul.   

Abstract

Apalcillin, a naphthydridine derivative of ampicillin, was compared with ticarcillin, azlocillin, mezlocillin, piperacillin, cefotaxime, and cefoperazone against gram-negative and gram-positive bacterial isolates and with cefsulodin and tobramycin against Pseudomonas aeruginosa. The minimal concentrations of apalcillin at which 50 and 90% of hospital isolates of Escherichia coli were inhibited were similar to those of mezlocillin and piperacillin (1.6 and 100 micrograms/ml, respectively). Apalcillin had minimal inhibitory concentrations similar to those of piperacillin against Citrobacter freundii and Citrobacter diversus. Against Klebsiella, apalcillin inhibited 50% of organisms at a concentration of 6.3 micrograms/ml, similar to piperacillin. The activity of apalcillin against Enterobacter (E. aerogenes, E. cloacae, and E. agglomerans) was similar to that of mezlocillin and piperacillin and greater than that of ticarcillin. The activity of apalcillin against Proteus mirabilis was similar to that of the other agents, as was its activity against indole-positive Proteus and Providencia. Only 40% of Serratia were inhibited at an apalcillin concentration of 25 micrograms/ml. Apalcillin was as active as piperacillin but twofold less active than cefoxitin or moxalactam against Bacteroides fragilis. It was as active as piperacillin, cefoperazone, and cefsulodin against P. aeruginosa (apalcillin inhibited 90% of organisms at a concentration of 25 mg/ml). There was an inoculum effect and a difference in the minimal inhibitory concentration and minimal bactericidal concentration with beta-lactamase strains. Apalcillin was hydrolyzed by plasmid beta-lactamase but not as well by cephalosporinases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981375      PMCID: PMC182044          DOI: 10.1128/AAC.21.6.906

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates.

Authors:  H Noguchi; M Kubo; S Kurashige; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

2.  New antipseudomonal penicillin, PC-904: affinity to penicillin-binding proteins and inhibition of the enzyme cross-linking peptidoglycan.

Authors:  H Noguchi; M Matsuhashi; M Takaoka; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

3.  Comparative studies of penicillin-binding proteins in Pseudomonas aeruginosa and Escherichia coli.

Authors:  H Noguchi; M Matsuhashi; S Mitsuhashi
Journal:  Eur J Biochem       Date:  1979-10

4.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  PC-904, a new semisynthetic penicillin.

Authors:  G P Bodey; S Weaver; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

6.  Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

7.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

  7 in total
  11 in total

1.  Comparative pharmacokinetics of apalcillin and piperacillin.

Authors:  H Lode; A Elvers; P Koeppe; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  Pharmacokinetics and bacteriological efficacies of apalcillin and cefpiramide in experimental pneumococcal meningitis.

Authors:  K Sato; S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

3.  Activity of apalcillin against Pseudomonas aeruginosa.

Authors:  G E Hollick; J Gundrum; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones; T L Gavan
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

5.  In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers.

Authors:  A L Barry; R N Jones; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  [Cefsulodin in the treatment of Pseudomonas meningitis].

Authors:  O Brückner; H Collmann; M Trautmann
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

8.  Biliary elimination of apalcillin in humans.

Authors:  J M Brogard; J P Arnaud; J F Blickle; J Lavillaureix
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

9.  Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

Authors:  J D Allan; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

10.  In vitro inactivation of aminoglycosides by apalcillin.

Authors:  D N Wright; D C Hale; B Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.